M.D. Anderson Cancer Center
To understand the severity and nature of participants experiences during irAEs following immune checkpoint inhibitor immunotherapy.
1. To understand the severity and nature of participants experiences during rheumatic immune-related adverse events following immune checkpoint inhibitor immunotherapy, including their functional impact 2. To explore domains relevant to participants experiencing rheumatic immune-related adverse events following immune checkpoint inhibitor immunotherapy, and attitudes to domains identified from the literature
Inclusion Criteria The criteria are: * Patients aged 18 years and above * English (conversational level) speaking, with the ability to give informed consent * Patients with a rheumatologist clinician diagnosis of inflammatory arthritis irAE or PMR irAE following ICI therapy Exclusion Criteria * Acutely life-threatening or worsening cancer * Hearing impairment functionally limiting participation in verbal interview
Arctuva estimate
Verify or correct the compensation shown for this listing.